Ignite Creation Date:
2025-12-25 @ 4:14 AM
Ignite Modification Date:
2025-12-26 @ 3:13 AM
Study NCT ID:
NCT05972720
Status:
TERMINATED
Last Update Posted:
2025-05-15
First Post:
2023-07-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Sponsor:
CARGO Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | CD-22 Expressing Tumor | View |
| None | Chimeric Antigen Receptor | View |
| None | Adoptive Immunotherapy | View |
| None | Lymphoma, B-Cell | View |
| None | Lymphoma, Large B-Cell, Diffuse | View |
| None | Lymphoma, Primary Mediastinal B-cell | View |
| None | Lymphoma, Transformed | View |
| None | Lymphoma, Transformed Non-Hodgkin | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | CAR T | View |
| None | CAR T-cell therapy | View |
| None | Cell Therapy | View |
| None | Cellular Immuno-therapy | View |
| None | CRG-022 | View |
| None | CD22 | View |
| None | FIRCE-1 | View |
| None | firicabtagene autoleucel | View |
| None | firi-cel | View |